NEW YORK, June 01, 2017 (GLOBE NEWSWIRE) -- Mid Atlantic Bio Angels (MABA) announces today that Recensa Therapeutics (, which is developing a topical psoriasis treatment designed to reduce oxidative stress, was named “Best in Show” by the audience and “Most Fundable” by the investor panel at MABA's 1st Pitch Life Science event held on May 25, 2017 at Rockefeller University in New York City.

Recensa Therapeutics was also names one of the Best University Startups 2017 at NCET2's 2nd University Startups Demo Day.

Read full article here:

Please publish modules in offcanvas position.